Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
出版年份 2023 全文链接
标题
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
作者
关键词
-
出版物
YONSEI MEDICAL JOURNAL
Volume 64, Issue 2, Pages 86
出版商
Yonsei University College of Medicine
发表日期
2023-01-10
DOI
10.3349/ymj.2022.0244
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
- (2022) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
- (2022) Karim Fizazi et al. LANCET
- A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
- (2021) Seonggyu Byeon et al. BMC CANCER
- Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
- (2021) Hannah L. Rush et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- European cancer mortality predictions for the year 2020 with a focus on prostate cancer
- (2020) G. Carioli et al. ANNALS OF ONCOLOGY
- Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
- (2020) William T. Lowrance et al. JOURNAL OF UROLOGY
- A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
- (2019) Sang Eun Yoon et al. BMC Urology
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
- (2018) C L Vale et al. ANNALS OF ONCOLOGY
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
- (2018) M R Sydes et al. ANNALS OF ONCOLOGY
- Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia
- (2018) Darren M. C. Poon et al. Asia-Pacific Journal of Clinical Oncology
- Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease
- (2018) Antoine Finianos et al. Clinical Genitourinary Cancer
- Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
- (2018) Alicia K. Morgans et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
- (2018) Susan Feyerabend et al. EUROPEAN JOURNAL OF CANCER
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis
- (2018) Jean-Michel Lavoie et al. PROSTATE
- The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial
- (2017) Nobumichi Tanaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
- (2016) Marcello Tucci et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy
- (2016) In Gab Jeong et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea
- (2010) Jae-Lyun Lee et al. Cancer Research and Treatment
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation